E Fund Management Co. Ltd. Purchases 2,343 Shares of Moderna, Inc. (NASDAQ:MRNA)

E Fund Management Co. Ltd. lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 21.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 13,037 shares of the company’s stock after acquiring an additional 2,343 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Moderna were worth $1,548,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Moderna in the second quarter worth about $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the fourth quarter worth about $27,000. Cedar Wealth Management LLC increased its holdings in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna in the first quarter worth about $32,000. Finally, Family Firm Inc. bought a new stake in shares of Moderna in the second quarter worth about $33,000. 75.33% of the stock is owned by institutional investors.

Moderna Trading Up 4.1 %

MRNA opened at $71.99 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock has a market cap of $27.59 billion, a price-to-earnings ratio of -4.59 and a beta of 1.68. The stock’s 50 day moving average price is $93.23 and its 200-day moving average price is $111.56. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($3.62) earnings per share. On average, equities analysts forecast that Moderna, Inc. will post -9.52 EPS for the current year.

Analyst Upgrades and Downgrades

MRNA has been the topic of several analyst reports. Hsbc Global Res raised Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Leerink Partners reduced their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Evercore ISI reissued an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Finally, Royal Bank of Canada reduced their price objective on Moderna from $90.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $100.44.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 689 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares of the company’s stock, valued at approximately $174,665,819.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 689 shares of the stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,158 shares of company stock worth $11,167,312. Company insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.